Trial Profile
Phase II Trial of Durvalumab (MEDI4736 )/Tremelimumab Combined With Definitive Concurrent Chemo-radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2022
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cisplatin; Fluorouracil
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 23 Mar 2022 Status changed from active, no longer recruiting to completed, according to Results published in the Cancer.
- 23 Mar 2022 Primary endpoint (Progression-free survival) has been met, according to Results published in the Cancer.
- 23 Mar 2022 Results published in the Cancer.